Isotechnika Pharma Inc IPHAF

The "REAL" powerhouse franchise-VELOXIS

[ISAloser247]

..I'm sure that when putting on his T-shirt, or trimming his muttons, the thought of VELOXIS pharmacuetical, must be rattling in his skull. With a product candidate, LCP-Tarco in a fully-enrolled Phase 3 study for the treatment of kidney transplant patients, and with NDA/MMA submission in the U.S. and EU, respectively expected in the first half of 2013, diddling around an arbitration hearing is not what a "powerhouse franchise" should be doing!   LCP-Tarco is being developed as a once-daily dosage version of tacrolimus for the treatment of kidney and liver transplant patients. Wonder why narcissist, snkid, thrumud, two-face, never brought VELO on the NASDAQ , in comparision of treatments? If You were a transplant surgeon, which would You prefer for a patient?........watching the Home Shopping Channel must swayTheir judgements!

[go4future]

Sure, they have a fully enrolled Phase 3b study, but the study includes the following program, STRATO which is being used in part to address tremor (neurotoxicity) issues with tacrolimus and will be required as any advantage of moving forward with LCP-Tacro and regulatory approval if it is somewhat successful in proving. This is something that VCS has already for the low-dose as per PROMISE study,

[go4future]

Sure, they have a fully enrolled Phase 3b study, but the study includes the following program, STRATO which is being used in part to address tremor (neurotoxicity) issues with tacrolimus and will be required as any advantage of moving forward with LCP-Tacro and regulatory approval if it is somewhat successful in proving. This is something that VCS has already for the low-dose as per PROMISE study,